Hepatic volumetry to predict adverse events in percutaneous ablation of hepatocellular carcinoma

Yujin Hoshida, Yasushi Shiratori, Yukihiro Koike, Shuntaro Obi, Keisuke Hamamura, Takuma Teratani, Shuichiro Shiina, Masao Omata

Research output: Contribution to journalArticle

16 Citations (Scopus)

Abstract

Background/Aims: This study aimed to clarify the relation of hepatic volumetry to adverse events after percutaneous transhepatic ablation for hepatocellular carcinoma. Methodology: One hundred and forty-nine patients with hepatocellular carcinoma who underwent percutaneous ablation sessions with complete ablation of cancer nodules, underwent volume measurement of the entire liver, tumor, and ablated area using computed tomography. The parenchymal ablation rate was calculated: (ablated volume-tumor volume)/(entire liver volume-tumor volume) × 100 (%). Other clinical parameters were also analyzed to determine their relationship to adverse events. Results: The median adjusted liver volume was 591mL/body surface area (m2) (range: 300 to 1197mL/m2). The median parenchymal ablation rate was 2.3% (range: 0.2% to 20.2%). Adverse events were observed in 17 patients after percutaneous ablation: liver abscess in 3, hepatic infarction in 3, portal vein thrombus in 3, hemobilia in 1, pleural effusion and/or ascites in 6, and gastric ulcer in 1. Multivariate analysis showed that Child B or C (P=0.0009), adjusted liver volume <600mL/m2 (P=0.0004), and parenchymal ablation rate >5% (P=0.0320) were independent risk factors for adverse events. Conclusions: Measurement of liver volume and parenchymal ablation rate are useful to predict the presence of percutaneous ablation-related adverse events.

Original languageEnglish (US)
Pages (from-to)451-455
Number of pages5
JournalHepato-Gastroenterology
Volume49
Issue number44
StatePublished - Jan 1 2002
Externally publishedYes

Fingerprint

Hepatocellular Carcinoma
Liver
Tumor Burden
Hemobilia
Liver Abscess
Body Surface Area
Pleural Effusion
Stomach Ulcer
Portal Vein
Ascites
Infarction
Neoplasms
Thrombosis
Multivariate Analysis
Tomography

Keywords

  • Adverse event
  • Hepatocellular carcinoma
  • Percutaneous ethanol injection
  • Radiofrequency ablation
  • Volumetry

ASJC Scopus subject areas

  • Hepatology
  • Gastroenterology

Cite this

Hoshida, Y., Shiratori, Y., Koike, Y., Obi, S., Hamamura, K., Teratani, T., ... Omata, M. (2002). Hepatic volumetry to predict adverse events in percutaneous ablation of hepatocellular carcinoma. Hepato-Gastroenterology, 49(44), 451-455.

Hepatic volumetry to predict adverse events in percutaneous ablation of hepatocellular carcinoma. / Hoshida, Yujin; Shiratori, Yasushi; Koike, Yukihiro; Obi, Shuntaro; Hamamura, Keisuke; Teratani, Takuma; Shiina, Shuichiro; Omata, Masao.

In: Hepato-Gastroenterology, Vol. 49, No. 44, 01.01.2002, p. 451-455.

Research output: Contribution to journalArticle

Hoshida, Y, Shiratori, Y, Koike, Y, Obi, S, Hamamura, K, Teratani, T, Shiina, S & Omata, M 2002, 'Hepatic volumetry to predict adverse events in percutaneous ablation of hepatocellular carcinoma', Hepato-Gastroenterology, vol. 49, no. 44, pp. 451-455.
Hoshida Y, Shiratori Y, Koike Y, Obi S, Hamamura K, Teratani T et al. Hepatic volumetry to predict adverse events in percutaneous ablation of hepatocellular carcinoma. Hepato-Gastroenterology. 2002 Jan 1;49(44):451-455.
Hoshida, Yujin ; Shiratori, Yasushi ; Koike, Yukihiro ; Obi, Shuntaro ; Hamamura, Keisuke ; Teratani, Takuma ; Shiina, Shuichiro ; Omata, Masao. / Hepatic volumetry to predict adverse events in percutaneous ablation of hepatocellular carcinoma. In: Hepato-Gastroenterology. 2002 ; Vol. 49, No. 44. pp. 451-455.
@article{17c441bba3c34252a7bb342c00596905,
title = "Hepatic volumetry to predict adverse events in percutaneous ablation of hepatocellular carcinoma",
abstract = "Background/Aims: This study aimed to clarify the relation of hepatic volumetry to adverse events after percutaneous transhepatic ablation for hepatocellular carcinoma. Methodology: One hundred and forty-nine patients with hepatocellular carcinoma who underwent percutaneous ablation sessions with complete ablation of cancer nodules, underwent volume measurement of the entire liver, tumor, and ablated area using computed tomography. The parenchymal ablation rate was calculated: (ablated volume-tumor volume)/(entire liver volume-tumor volume) × 100 ({\%}). Other clinical parameters were also analyzed to determine their relationship to adverse events. Results: The median adjusted liver volume was 591mL/body surface area (m2) (range: 300 to 1197mL/m2). The median parenchymal ablation rate was 2.3{\%} (range: 0.2{\%} to 20.2{\%}). Adverse events were observed in 17 patients after percutaneous ablation: liver abscess in 3, hepatic infarction in 3, portal vein thrombus in 3, hemobilia in 1, pleural effusion and/or ascites in 6, and gastric ulcer in 1. Multivariate analysis showed that Child B or C (P=0.0009), adjusted liver volume <600mL/m2 (P=0.0004), and parenchymal ablation rate >5{\%} (P=0.0320) were independent risk factors for adverse events. Conclusions: Measurement of liver volume and parenchymal ablation rate are useful to predict the presence of percutaneous ablation-related adverse events.",
keywords = "Adverse event, Hepatocellular carcinoma, Percutaneous ethanol injection, Radiofrequency ablation, Volumetry",
author = "Yujin Hoshida and Yasushi Shiratori and Yukihiro Koike and Shuntaro Obi and Keisuke Hamamura and Takuma Teratani and Shuichiro Shiina and Masao Omata",
year = "2002",
month = "1",
day = "1",
language = "English (US)",
volume = "49",
pages = "451--455",
journal = "Acta hepato-splenologica",
issn = "0172-6390",
publisher = "H.G.E. Update Medical Publishing Ltd.",
number = "44",

}

TY - JOUR

T1 - Hepatic volumetry to predict adverse events in percutaneous ablation of hepatocellular carcinoma

AU - Hoshida, Yujin

AU - Shiratori, Yasushi

AU - Koike, Yukihiro

AU - Obi, Shuntaro

AU - Hamamura, Keisuke

AU - Teratani, Takuma

AU - Shiina, Shuichiro

AU - Omata, Masao

PY - 2002/1/1

Y1 - 2002/1/1

N2 - Background/Aims: This study aimed to clarify the relation of hepatic volumetry to adverse events after percutaneous transhepatic ablation for hepatocellular carcinoma. Methodology: One hundred and forty-nine patients with hepatocellular carcinoma who underwent percutaneous ablation sessions with complete ablation of cancer nodules, underwent volume measurement of the entire liver, tumor, and ablated area using computed tomography. The parenchymal ablation rate was calculated: (ablated volume-tumor volume)/(entire liver volume-tumor volume) × 100 (%). Other clinical parameters were also analyzed to determine their relationship to adverse events. Results: The median adjusted liver volume was 591mL/body surface area (m2) (range: 300 to 1197mL/m2). The median parenchymal ablation rate was 2.3% (range: 0.2% to 20.2%). Adverse events were observed in 17 patients after percutaneous ablation: liver abscess in 3, hepatic infarction in 3, portal vein thrombus in 3, hemobilia in 1, pleural effusion and/or ascites in 6, and gastric ulcer in 1. Multivariate analysis showed that Child B or C (P=0.0009), adjusted liver volume <600mL/m2 (P=0.0004), and parenchymal ablation rate >5% (P=0.0320) were independent risk factors for adverse events. Conclusions: Measurement of liver volume and parenchymal ablation rate are useful to predict the presence of percutaneous ablation-related adverse events.

AB - Background/Aims: This study aimed to clarify the relation of hepatic volumetry to adverse events after percutaneous transhepatic ablation for hepatocellular carcinoma. Methodology: One hundred and forty-nine patients with hepatocellular carcinoma who underwent percutaneous ablation sessions with complete ablation of cancer nodules, underwent volume measurement of the entire liver, tumor, and ablated area using computed tomography. The parenchymal ablation rate was calculated: (ablated volume-tumor volume)/(entire liver volume-tumor volume) × 100 (%). Other clinical parameters were also analyzed to determine their relationship to adverse events. Results: The median adjusted liver volume was 591mL/body surface area (m2) (range: 300 to 1197mL/m2). The median parenchymal ablation rate was 2.3% (range: 0.2% to 20.2%). Adverse events were observed in 17 patients after percutaneous ablation: liver abscess in 3, hepatic infarction in 3, portal vein thrombus in 3, hemobilia in 1, pleural effusion and/or ascites in 6, and gastric ulcer in 1. Multivariate analysis showed that Child B or C (P=0.0009), adjusted liver volume <600mL/m2 (P=0.0004), and parenchymal ablation rate >5% (P=0.0320) were independent risk factors for adverse events. Conclusions: Measurement of liver volume and parenchymal ablation rate are useful to predict the presence of percutaneous ablation-related adverse events.

KW - Adverse event

KW - Hepatocellular carcinoma

KW - Percutaneous ethanol injection

KW - Radiofrequency ablation

KW - Volumetry

UR - http://www.scopus.com/inward/record.url?scp=0036016503&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0036016503&partnerID=8YFLogxK

M3 - Article

C2 - 11995472

AN - SCOPUS:0036016503

VL - 49

SP - 451

EP - 455

JO - Acta hepato-splenologica

JF - Acta hepato-splenologica

SN - 0172-6390

IS - 44

ER -